Merit Medical Systems Inc.
04/13/2026 | Press release | Distributed by Public on 04/13/2026 14:12
Regulation FD Disclosure (Form 8-K)
Item 7.01 Regulation FD Disclosure
The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished by Merit Medical Systems, Inc. ("Merit") to provide historical revenue information disaggregated by its new foundational and therapeutic product categories for the years ended December 31, 2025, 2024, 2023, and 2022, as well as quarterly revenue information for each of the three-month periods ended March 31, 2024 to December 31, 2025. Merit is providing this historical revenue information for the purpose of aiding period-over-period comparisons for the years and three-month periods indicated. The historical revenue information does not constitute a revision or restatement of Merit's previously reported consolidated financial statements.
Merit's revenue under the new product categories for the years ended December 31, 2025, 2024, 2023 and 2022, respectively, was as follows (unaudited, in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
||||||||||
|
|
|
2025 |
|
2024 |
|
2023 |
|
2022 |
||||
|
Foundational |
|
$ |
1,028,540 |
|
$ |
964,100 |
|
$ |
926,253 |
|
$ |
862,375 |
|
Therapeutic |
|
|
487,366 |
|
392,414 |
|
331,113 |
|
288,606 |
|||
|
Total |
|
$ |
1,515,906 |
|
$ |
1,356,514 |
|
$ |
1,257,366 |
|
$ |
1,150,981 |
Merit's revenue under the new product categories for the three-month periods ended March 31, June 30, September 30, and December 31, 2025, compared to the corresponding periods of 2024, was as follows (unaudited, in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three-Month Period Ended |
||||||||||
|
2025 |
|
March 31 |
|
June 30 |
|
September 30 |
|
December 31 |
||||
|
Foundational |
|
$ |
240,382 |
|
$ |
262,382 |
|
$ |
260,906 |
|
$ |
264,870 |
|
Therapeutic |
|
|
114,969 |
|
120,080 |
|
123,251 |
|
129,066 |
|||
|
Total |
|
$ |
355,351 |
|
$ |
382,462 |
|
$ |
384,157 |
|
$ |
393,936 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three-Month Period Ended |
||||||||||
|
2024 |
|
March 31 |
|
June 30 |
|
September 30 |
|
December 31 |
||||
|
Foundational |
|
$ |
232,930 |
|
$ |
245,404 |
|
$ |
240,742 |
|
$ |
245,024 |
|
Therapeutic |
|
|
90,578 |
|
92,599 |
|
99,103 |
|
110,134 |
|||
|
Total |
|
$ |
323,508 |
|
$ |
338,003 |
|
$ |
339,845 |
|
$ |
355,158 |
2
Merit is providing historical revenue information under each product category by product platform for the years ended December 31, 2025, 2024, 2023 and 2022. Such supplemental information is presented for the purpose of providing additional details regarding Merit's current revenue categories. Merit does not intend to provide revenue information disaggregated by product platform on a recurring basis in future periods.
Merit's revenue by product platform for the years ended December 31, 2025, 2024, 2023 and 2022, respectively, was as follows (unaudited, in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
||||||||||
|
|
|
2025 |
|
2024 |
|
2023 |
|
2022 |
||||
|
Foundational |
|
|
|
|
|
|
|
|
|
|
|
|
|
Access |
|
$ |
588,542 |
|
$ |
538,272 |
|
$ |
527,440 |
|
$ |
498,375 |
|
OEM |
|
|
167,086 |
|
|
165,420 |
|
|
150,480 |
|
|
135,066 |
|
Procedural Solutions |
|
|
124,717 |
|
|
117,198 |
|
|
114,233 |
|
|
116,763 |
|
Vascular Intervention |
|
|
139,997 |
|
|
132,284 |
|
|
119,883 |
|
|
102,663 |
|
Other |
|
|
8,198 |
|
|
10,926 |
|
|
14,217 |
|
|
9,508 |
|
Total Foundational |
|
|
1,028,540 |
|
|
964,100 |
|
|
926,253 |
|
|
862,375 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Therapeutic |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cardiac Therapies |
|
|
93,357 |
|
|
49,436 |
|
|
36,415 |
|
|
33,632 |
|
Endoscopy |
|
|
72,481 |
|
|
54,415 |
|
|
37,019 |
|
|
31,912 |
|
OEM |
|
40,464 |
|
39,886 |
|
42,681 |
|
|
38,079 |
|||
|
Oncology |
|
|
96,805 |
|
|
86,940 |
|
|
77,761 |
|
|
67,406 |
|
Renal Therapies |
|
|
52,802 |
|
|
48,980 |
|
|
36,547 |
|
|
21,826 |
|
Vascular Intervention |
|
|
131,457 |
|
|
112,757 |
|
|
100,690 |
|
|
95,751 |
|
Total Therapeutic |
|
|
487,366 |
|
|
392,414 |
|
|
331,113 |
|
|
288,606 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
1,515,906 |
|
$ |
1,356,514 |
|
$ |
1,257,366 |
|
$ |
1,150,981 |
The information contained in this Item 7.01 of this Current Report is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended (the "Securities Act"), or the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Merit Medical Systems Inc. published this content on April 13, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 13, 2026 at 20:12 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]